医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsubishi Tanabe Pharma Corporation Signs Licensing Agreement with A. Menarini Asia-Pacific for Spedra (Avanafil) in 10 Countries in Asia-Pacific

2016年02月26日 PM05:59
このエントリーをはてなブックマークに追加


 

SINGAPORE

Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini AP”) have entered into a licensing agreement to commercialize and promote SPEDRA™ (avanafil). Menarini AP will receive exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam.

Menarini AP is a member of the Menarini Group, the world’s largest Italian biopharmaceutical company, and provides physicians and healthcare professionals with medical and scientific information with competence, correctness and the highest ethical standards in all its work processes. Menarini Group has already been licensed to market this product in over 40 European countries, plus Australia and New Zealand.

SPEDRA™ (avanafil) is a new and innovative phosphodiesterase – 5 inhibitor (PDE5-i) approved by the European Commission in June 2013 for the treatment of erectile dysfunction. In the U.S., FDA approved avanafil in April 2012 for the same indication, under the trade name STENDRA™.

“A. Menarini Asia-Pacific is an ideal partner in this region. With its extensive reach to the physicians and urologists/andrologists in the region, strong core values, and established track record in product launch, we are delighted to partner with Menarini AP”, commented Mr. Masayuki Mitsuka, President and Representative Director at Mitsubishi Tanabe Pharma Corporation.

“The Asia Pacific Erectile Dysfunction (ED) market is poised to grow strongly in the foreseeable future, driven by improvements in diagnosis rates, patient’s affordability and improvements in access to quality healthcare. SPEDRA™ is a welcome addition to our men’s health portfolio as it represents an innovative treatment option for men with erectile dysfunction (ED) due to its unique pharmacological characteristics and rapid onset of action. Together with Priligy, the first approved drug for premature ejaculation (PE), Menarini AP has further consolidated its presence in the men’s health space in the region”, said Dr. Luca Lastrucci, CEO at A. Menarini Asia-Pacific.

About Spedra (Avanafil)

Avanafil is a second generation, highly selective and potent PDE5 inhibitor. Due to its unique pharmacokinetic profile, Avanafil has shown to be efficacious within approximately 15 minutes of dosing in most patients, thus representing the only PDE5-I approved in Europe to be taken 15 to 30 minutes before sexual activity. Along with the fast onset of action, Avanafil has shown a good tolerability profile with a low incidence of class related adverse events in clinical trials. SPEDRA™, the trade name for Avanafil in the EU, has been approved by the European Medicines Agency for the treatment of erectile dysfunction. Known as STENDRA in the U.S., it is also approved by the Food and Drug Administration in the U.S. for the treatment of erectile dysfunction. Mitsubishi Tanabe Pharma Corporation owns development and commercial rights to avanafil for the treatment of male sexual dysfunction in certain Asia-Pacific Rim countries.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC) is a research-driven pharmaceutical company based in Osaka, Japan. MTPC is taking on the challenge of drug discovery in the fields of autoimmune disorders, central nervous system diseases, diabetes and kidney diseases, and vaccines. To those ends, MTPC is strengthening its R&D pipeline. MTPC contributes to the healthier lives of people around the world through the creation of pharmaceuticals.

For more information about MTPC, please visit: http://www.mt-pharma.co.jp/e

About Menarini Asia-Pacific

Menarini Asia-Pacific is part of the Menarini Group, the world’s largest Italian biopharmaceutical company with a heritage of over 130 years and over 16,000 highly trained employees operating in more than 100 countries according to strict ethical principles. Menarini Asia-Pacific’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Cardiovascular, Oncology/Specialty Care and Men’s Health.

For more information about Menarini Asia-Pacific, please visit: www.menariniapac.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160226005251/en/

CONTACT

A. Menarini Asia-Pacific Holdings Pte Ltd
Jennifer Lin, +65-64943427
Senior
Regional Corporation Branding & Communications Manager
JenniferCW.lin@menariniapac.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease